-
Infantino defends World Cup ticket prices
-
Pistons hold off Cavs to win series-opener
-
Rubio rising? Duel with Vance for 2028 heats up
-
Teen shooter kills two at Brazil school
-
US pauses Hormuz escorts in bid for deal, as threats continue
-
Judge orders German car-ramming suspect to psychiatric hospital
-
Fresh UAE attacks blamed on Iran draw new reality in the Gulf
-
Arsenal on cusp of history after reaching Champions League final
-
Trump says pausing Hormuz operation in push for Iran deal
-
Wembanyama accused of 'obvious' illegal blocking
-
Musk 'was going to hit me,' OpenAI executive says at trial
-
NFL star Diggs cleared of assaulting personal chef
-
Fans 'set the standards' at rocking Emirates: Arteta
-
Rubio warns against 'destabilizing' acts on Taiwan before Trump China visit
-
US declares Iran offensive over, warns force remains an option
-
Saka ends Arsenal's 20-year wait to reach Champions League final
-
Outgoing Costa Rica leader secures top post in new cabinet
-
Rubio plays down Trump attacks on pope before Vatican trip
-
LIV Golf boss sees hope for new sponsors beyond 2026
-
Mexican BTS fans go wild as concerts grow near
-
Europe's first commercial robotaxi service rolls out in Croatia
-
Russian strikes kill 21 in Ukraine
-
Suspected hantavirus cases to be evacuated from cruise ship
-
G7 trade ministers meet, not expected to discuss US tariff threat
-
Hollywood star Malkovich gets Croatian citizenship
-
Mickelson pulls out of PGA Championship for family issues
-
Wales rugby great Halfpenny to retire
-
Rahm says player concessions needed to save LIV Golf
-
Bowlers, Samson keep Chennai afloat in IPL playoff race
-
Rolling Stones announce July 10 release of new album 'Foreign Tongues'
-
France's Macron taps ex-aide to head central bank
-
PSG 'not here to defend' against Bayern, says Luis Enrique
-
Trump says he works out 'one minute a day' as he restores fitness award
-
Russia hits Ukraine with deadly strikes as Zelensky denounces Moscow's 'cynicism'
-
EU urges US to stick to tariff deal terms
-
Hantavirus on the Hondius: what we know
-
Rahm eligible for Ryder Cup after deal with European Tour
-
Stocks rise, oil falls as traders eye earnings, US-Iran ceasefire
-
Bayern's Kompany channels 'inner tranquility' before PSG showdown
-
Colombian mine explosion kills nine
-
Matthews latest England World Cup-winner out of Women's Six Nations
-
Race to find port for cruise ship battling deadly rodent virus
-
Celtic's O'Neill says Hearts' rise good for Scottish football
-
Ethiopia and Sudan accuse each other of attacks
-
Injured Mbappe faces backlash over Sardinia trip before Clasico
-
Vodafone to take full ownership of UK mobile operator
-
Stocks advance, oil falls as traders eye US-Iran ceasefire
-
Sabalenka ready to boycott Grand Slams over prize money
-
Boko Haram attack on Chad army base kills at least 24: military, local officials
-
US trade gap widens in March as AI spending boosts imports
US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
L.E.Campos--PC